Skip to content

Comparison of Two Treatment Regimens of Helicobacter Pylori Infection

Comparison of Conventional Clarithromycin Vs Alternative Levofloxacin Based Regimen in Treatment of Helicobacter Pylori Infection

Status
Not yet recruiting
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07021729
Enrollment
156
Registered
2025-06-15
Start date
2025-12-31
Completion date
2026-06-30
Last updated
2025-06-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Helicobacter Pylori Infection

Keywords

clarithromycin, levofloxacin, helicobacter pylori

Brief summary

The goal of this interventional study is to compare the efficacy of clarithromycin Vs levofloxacin based regimen in treatment of Helicobacter pylori infection in patients presenting to medical OPD who are tested positive for H pylori infection.. The main question\[s\] it aims to answer are: • Which regimen is superior in terms of efficacy Participants will be treated for H pylori Infection in with two different regimen If there is a comparison group: Researchers will compare two groups Group 1 will receive clarithromycin based regimen group 2 will receive levofloxacin based regimen to see the treatment response.

Detailed description

This interventional study will be conducted in department of medicine, Rehman Medical Institute, Peshawar. Study duration: 10 months after the issuance of ethical approval Sample size: Sample size is calculated using a two-tailed alpha test with a significance level of 0.05 and 90% power to detect 23% difference in the eradication rate of the two regimens. The total number of patients required to prove the hypothesis is 156, 78 in each group. Study population: Patients coming to OPD with symptoms suggestive of H pylori infection will undergo screening by Hpylori stool antigen. If it comes to be positive then they will be enrolled in study after applying inclusion/exclusion criteria. Inclusion criteria: All patients who tested positive on stool antigen will be included. Age \>12 years and both genders will be included. Exclusion criteria: patients under 12 years old. Patients who have penicillin allergy. Patients who have underlying dysrhythmia forbidding the use of macrolide. Patient who have hypersensitivity to any of these antibiotics. Study population will be divided in two groups. Group 1 will receive regimen number 1 and group 2 will receive regimen number 2.( regimens are described below.) Regimen 1 (R1): Clarithromycin 500mg BD, plus metronidazole 400mg TDS for 14days and Omeprazole 40mg BD for 6 weeks. Regimen 2(R2): Levofloxacin 500mg OD plus Amoxicillin 1gm BD for 14 days and omeprazole 40mg Bd for 6 weeks. The patients will be followed 2 weeks after completion of treatment. On follow up, their symptoms improvement, compliance and side effects will be documented. They will undergo stool Ag test again to assess treatment response.

Interventions

DRUGClarithromycin

Drug regimens will be given for 14 days, and omeprazole for 6weeks

DRUGLevofloxacin

Drug regimens will be given for 14 days, and omeprazole for 6weeks

Sponsors

Rehman Medical Institute - RMI
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
12 Years to 90 Years
Healthy volunteers
No

Inclusion criteria

* All patients who tested positive on stool antigen will be included.

Exclusion criteria

* patients under 12 years old. Patients who have penicillin allergy. * Patients who have underlying dysrhythmia forbidding the use of macrolide. * Patient who have hypersensitivity to any of these antibiotics.

Design outcomes

Primary

MeasureTime frameDescription
Treatment of H pylori infection2weeks after completion of treatment regimenTreatment of H pylori infection documented by negative stool antigen

Contacts

Primary ContactWajeeha Qayyum, FCPS
wajeeha.qayyum@rmi.edu.pk092915838000
Backup ContactTaimur Khan, FCPS
taimur.khan@rmi.edu.pk092915838000

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026